drugset / Trial / NCT01928225

Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

NCT01928225

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors. This study will test whether giving the quadrivalent vaccine to women prior to surgical treatment of the cervical cancer precursor will improve outcomes. We hypothesize that pre-treatment HPV vaccine will result in a reduced occurrence or cervical cancer precursors in follow-up.

Timeline

Start
2014-09-02
Primary completion
2017-11-30
Completion
2018-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine